|Over a month ago|
Fly Intel: After-Hours Movers » 18:3506/1506/15/20
LMB, LMPX, WW, MBIO, AYI, VICI
Check out this evening's…
Mustang Bio CEO Litchman purchases $500K in company shares » 16:3906/1506/15/20
Mustang Bio CEO Manuel…
Mustang Bio CEO Manuel Litchman purchased 153,846 shares of company stock at an average price of $3.25 on June 11. The total transaction amount was $500,000.
Mustang Bio 10.79M share Spot Secondary priced at $3.25 » 09:1206/1106/11/20
Cantor Fitzgerald acted…
Cantor Fitzgerald acted as sole book running manager for the offering.
Fly Intel: Pre-market Movers » 08:5606/1106/11/20
SRNE, GRUB, HEXO, TLRD, PLCE, OXM, TSLA, MBIO
Check out this morning's…
Fly Intel: After-Hours Movers » 19:0206/1006/10/20
TLRD, JACK, GRUB, PSNL, SRT, OXM, MBIO, CTLT, CIM
Check out this evening's…
Mustang Bio files to sell common stock, no amount given » 16:0106/1006/10/20
Cantor Fitzgerald &…
Cantor Fitzgerald & Co. is acting as the sole book running manager for the offering.
Mustang Bio announces presentations at ASGCT meeting » 08:3905/1205/12/20
Mustang Bio announced two…
Mustang Bio announced two poster presentations at the virtual 23rd Annual Meeting of the American Society of Gene & Cell Therapy, being held May 12-15, 2020. Details on the poster presentations are as follows: Title: CS1 Targeted CAR-T Cells for the Treatment of Multiple Myeloma Shows Antitumor Activity Sparing Normal T-Cells Despite the Common Expression of CS1: This poster describes researchers' investigation into the impact of MB-104 on CS1 positive and negative cells in vitro, as well as T cells due to shared CS1 antigen expansion. The researchers demonstrated MB-104 does not confer biologically significant fratricide and can be successfully manufactured as evident by viability, growth kinetics and fold expansion, despite the shared antigen expression between tumor cells and T cells. CS1 positive T cells are present in culture during the expansion of MB-104, suggesting absence of fratricide. Finally, MB-104 can induce potent anti-tumor cell lysis and proliferates in response to tumor cells but not primary T cells expressing CS1. Taken together, their results demonstrate MB-104 is a novel CS1-targeting CAR T that shows potent anti-tumor cell lysis but spares normal T cells, despite the shared CS1 antigen expression. Title: Development of an Immunohistochemistry Assay for the Detection of CS-1 Expression in Multiple Myeloma Patients: This poster details a study in which researchers evaluated commercially available CS1 antibodies for IHC and identified the best clone with high specificity for CS1 to improve screening subjects for CS1 positive tumor expression prior to treatment and correlate efficacy with antigen expression. The researchers, for the first time, developed and optimized a robust immunohistochemistry assay for the assessment of CS1 expression in bone marrow core biopsy samples and plasmacytoma solid tumor samples from multiple myeloma patients, which can be used for enrollment into Mustang's CS1 CAR T clinical trials.
Mustang Bio receives ATMP classification for MB-107 lentiviral gene therapy » 08:0904/2004/20/20
Mustang Bio announced…
Mustang Bio announced that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification to MB-107, Mustang's lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease. The U.S. Food and Drug Administration previously granted Regenerative Medicine Advanced Therapy designation to MB-107 for the treatment of XSCID in August 2019. EMA grants ATMP classifications to new therapeutics that are based on genes or cells and intended as long-term or permanent therapeutic solutions to acute or chronic human diseases at a genetic, cellular or tissue level. The ATMP program provides specific regulatory guidelines for preclinical development, manufacturing and product quality testing of ATMPs and offers incentives, including fee reductions for regulatory advice, recommendations and evaluation and certification of quality and non-clinical data. MB-107 is currently being assessed in two Phase 1/2 clinical trials for XSCID: the first in newly diagnosed infants under the age of two at St. Jude Children's Research Hospital, UCSF Benioff Children's Hospital in San Francisco and Seattle Children's Hospital and the second in patients over the age of two who have received prior hematopoietic stem cell transplantation at the National Institutes of Health. Under a licensing partnership with St. Jude, Mustang intends to develop the lentiviral gene therapy for commercial use as MB-107.
|Over a quarter ago|
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright » 11:2502/1802/18/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Joseph Pantginis notes that Mustang Bio announced that its drug candidate MB-106 scored the first complete response in the first patient treated in the ongoing MB-106 Phase 1/2 trial. The analyst also points out that "this encouraging first clinical win" was observed following 28 days, after one single low dose of CARs and with no toxicity, such as cytokine release syndrome and neurotoxicity. Pantginis expects to see follow-up data of the trial at upcoming meetings, likely at ASH, by year-end 2020. The analyst has a Buy rating and $7 price target on the shares.
Mustang Bio announces first subject reated in Phase 1/2 trial of MB-106 » 08:1502/1802/18/20
Mustang Bio announced…
Mustang Bio announced that the first subject treated with the optimized MB-106 manufacturing process, developed in collaboration between Mustang and Fred Hutchinson Cancer Research Center has achieved a complete response at the lowest starting dose in an ongoing Phase 1/2 clinical trial. The trial is evaluating the safety and efficacy of MB-106 in subjects with relapsed or refractory B-cell non-Hodgkin lymphomas. The Phase 1/2, open-label, dose-escalation trial is evaluating the maximum tolerated dose of MB-106. Secondary endpoints include safety and toxicity, preliminary antitumor activity as measured by overall response rate and complete remission rate, progression-free survival, and overall survival. Fred Hutch intends to enroll approximately 30 subjects on the trial, which is being led by principal investigator Mazyar Shadman, M.D., M.P.H., Assistant Member of Fred Hutch's Clinical Research Division.